BioSpace News Archive

Research on current United States field medical affairs strategies indicates that industry engagement tactics are intensely changing

AlloSource®, one of the largest allograft providers in the U.S., creating innovative cellular and tissue products to help surgeons heal their patients, announced it is awarding Dr. Ergun Kocak with its fourth annual Dr. Steven Gitelis Inspiration Award.

Decisions should be made on a case-by-case basis, but return to school may be possible for majority of SOT children

The Ohio STEM Learning Network unveiled the four winners of the “STEM Excellence Awards.” These awards recognize outstanding teachers, school leaders, or education advocates who advance quality science, technology, engineering, and math education in Ohio.

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference.

SeaSpine Holdings Corporation, a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced financial results for the three months ended June 30, 2020.

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer,

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, today reported its results for the quarter ended June 30, 2020.

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended June 30, 2020.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced financial results for its second fiscal quarter ended June 30, 2020.